The Effectiveness of Brigatinib over Crizotinib for Treating Non-Small Cell Lung Cancer
Brigatinib / Alunbrig is a cancer medication belonging to the class of anaplastic lymphoma kinase inhibitor or ALK. It has been proven to be efficient in treating non-small cell lung cancer or NSCLC that is ALK positive.
The ALK gene occurs in only 3-5 % of the patients of NSCLC. Crizotinib (also a first generation ALK inhibitor) showed a longer progression-free survival when compared to platinum based double agent chemotherapy medication.
Source: https://shorturl.at/bilG6
The Effectiveness of Brigatinib over Crizotinib for Treating Non-Small Cell Lung Cancer
Brigatinib / Alunbrig is a cancer medication belonging to the class of anaplastic lymphoma kinase inhibitor or ALK. It has been proven to be efficient in treating non-small cell lung cancer or NSCLC that is ALK positive.
The ALK gene occurs in only 3-5 % of the patients of NSCLC. Crizotinib (also a first generation ALK inhibitor) showed a longer progression-free survival when compared to platinum based double agent chemotherapy medication.
Source: https://shorturl.at/bilG6
0 Comments
0 Shares